Department of Hepatology, Regional Institute of Gastroenterology and Hepatology "Octavian Fodor," "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Liver Unit, Barcelona Hepatic Hemodynamic Laboratory, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Semin Thromb Hemost. 2020 Sep;46(6):673-681. doi: 10.1055/s-0040-1715473. Epub 2020 Aug 20.
Portal vein thrombosis (PVT) is a frequent event in patients with cirrhosis regardless of etiology. Notwithstanding the commonality of the problem, the pathophysiology and risk factors for PVT in cirrhosis are largely unknown. The clinical impact of PVT in the natural history of cirrhosis is unclear, indications for PVT treatment are not well defined, and treatment recommendations are based on experts' opinion and consensus only. Therefore, this review aims to summarize current knowledge of mechanisms and risk factors for PVT development and assess the current evidence of PVT management, with a special focus on strategies of anticoagulation and transjugular intrahepatic portosystemic shunt placement.
门静脉血栓形成（PVT）是肝硬化患者的常见事件，无论病因如何。尽管这个问题很普遍，但肝硬化患者 PVT 的病理生理学和危险因素在很大程度上尚不清楚。PVT 在肝硬化自然病程中的临床影响尚不清楚，PVT 治疗的适应证也没有明确定义，治疗建议仅基于专家意见和共识。因此，本综述旨在总结目前关于 PVT 发展机制和危险因素的知识，并评估目前 PVT 管理的证据，特别关注抗凝和经颈静脉肝内门体分流术放置的策略。
